NAS:IONS (USA) Also trade in: Germany Switzerland UK

Ionis Pharmaceuticals Inc

$ 66.42 -2.14 (-3.12%)
Volume: 834,879 Avg Vol (1m): 1,371,088
Market Cap $: 9.35 Bil Enterprise Value $: 7.95 Bil
P/E (TTM): 26.59 P/B: 7.80
Earnings Power Value -5.01
Net Current Asset Value 5.27
Tangible Book 8.35
Projected FCF 20.4
Median P/S Value 69.01
Graham Number 21.72
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 3.37
Cash-To-Debt ranked lower than
66.79% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
IONS: 3.37
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.24, Med: 1.52, Max: 11.14
Current: 3.37
0.24
11.14
Equity-to-Asset 0.43
Equity-to-Asset ranked lower than
84.01% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
IONS: 0.43
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.85, Med: 0.35, Max: 0.8
Current: 0.43
-0.85
0.8
Debt-to-Equity 0.55
Debt-to-Equity ranked lower than
81.60% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
IONS: 0.55
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -19.36, Med: 0.9, Max: 742.15
Current: 0.55
-19.36
742.15
Debt-to-EBITDA 5.80
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
IONS: 5.8
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -61.12, Med: -8.88, Max: 16.72
Current: 5.8
-61.12
16.72
Interest Coverage 1.40
Interest Coverage ranked lower than
100.00% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
IONS: 1.4
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 0.69, Med: 0.69, Max: 1.4
Current: 1.4
0.69
1.4
Piotroski F-Score 7
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.76
DISTRESS
GREY
SAFE
Beneish M-Score -1.26
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 12.01%

Profitability & Growth : 6/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 8.43
Operating Margin ranked higher than
67.05% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
IONS: 8.43
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -71.76, Med: -24.68, Max: 8.43
Current: 8.43
-71.76
8.43
Net Margin % 47.79
Net Margin ranked higher than
68.94% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
IONS: 47.79
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -85.58, Med: -24.66, Max: 127.52
Current: 47.79
-85.58
127.52
ROE % 45.74
ROE ranked higher than
70.98% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
IONS: 45.74
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -40.77, Med: -22.23, Max: 86.43
Current: 45.74
-40.77
86.43
ROA % 15.91
ROA ranked higher than
76.48% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
IONS: 15.91
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -16.38, Med: -7.6, Max: 25.19
Current: 15.91
-16.38
25.19
ROC (Joel Greenblatt) % 78.62
ROC (Joel Greenblatt) ranked higher than
71.81% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
IONS: 78.62
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -152.05, Med: -55.1, Max: 78.62
Current: 78.62
-152.05
78.62
3-Year Total Revenue Growth Rate 28.30
3-Year Revenue Growth Rate ranked higher than
82.49% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
IONS: 23.6
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -39.5, Med: 7.2, Max: 83.7
Current: 23.6
-39.5
83.7
3-Year Total EBITDA Growth Rate 22.80
3-Year EBITDA Growth Rate ranked lower than
100.00% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
IONS: 25.6
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 2.45, Max: 49.7
Current: 25.6
0
49.7

» IONS's 30-Y Financials

Financials (Next Earnings Date: 2019-08-07)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:IONS

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare OCSE:GEN NAS:SGEN NAS:ALNY NAS:SRPT NAS:SAGE HKSE:01177 NAS:MRNA HKSE:02269 NAS:BLUE SZSE:000661 OCSE:NZYM B NAS:JAZZ NAS:TECH HKSE:06160 NAS:NBIX SZSE:002252 TSE:4587 NAS:AMRN XAMS:GLPG NAS:EXEL
Traded in other countries ISI.Germany 0JDI.UK
Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Ionis' broad clinical and preclinical pipeline consists treats a wide variety of diseases, with an emphasis on cardiovascular, metabolic, severe, and rare diseases. Ionis sold rights to its first product, Kynamro, to Kastle Therapeutics after lackluster commercial success, but with partner Biogen brought its second drug, Spinraza for spinal muscular atrophy, to market.

Ratios

Current vs industry vs history
PE Ratio (TTM) 26.59
PE Ratio ranked lower than
100.00% of 248 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.79, Min: 0.01
IONS: 26.59
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 5.56, Med: 31.29, Max: 1138.6
Current: 26.59
5.56
1138.6
PE Ratio without NRI 26.59
PE without NRI ranked lower than
100.00% of 243 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.64, Min: 0.01
IONS: 26.59
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 7.18, Med: 161.25, Max: 1138.6
Current: 26.59
7.18
1138.6
Price-to-Owner-Earnings 11.34
Price-to-Owner-Earnings ranked higher than
78.62% of 145 companies
in the Biotechnology industry.
Industry Max: 305714.29, Med: 34.35, Min: 0.21
IONS: 11.34
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 5.9, Med: 16.77, Max: 361.48
Current: 11.34
5.9
361.48
PB Ratio 7.80
PB Ratio ranked lower than
79.31% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
IONS: 7.8
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 3, Med: 9.81, Max: 65.21
Current: 7.8
3
65.21
PS Ratio 12.29
PS Ratio ranked higher than
51.10% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
IONS: 12.29
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 6.59, Med: 12.75, Max: 44.19
Current: 12.29
6.59
44.19
Price-to-Free-Cash-Flow 12.95
Price-to-Free-Cash-Flow ranked higher than
84.21% of 152 companies
in the Biotechnology industry.
Industry Max: 5923, Med: 37.07, Min: 0.04
IONS: 12.95
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 3.69, Med: 48.48, Max: 1346.3
Current: 12.95
3.69
1346.3
Price-to-Operating-Cash-Flow 12.58
Price-to-Operating-Cash-Flow ranked higher than
84.29% of 210 companies
in the Biotechnology industry.
Industry Max: 23050, Med: 29.99, Min: 0.04
IONS: 12.58
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 3.55, Med: 50.95, Max: 1474.69
Current: 12.58
3.55
1474.69
EV-to-EBIT 77.87
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
IONS: 77.87
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -699.2, Med: -21.7, Max: 1026.9
Current: 77.87
-699.2
1026.9
EV-to-EBITDA 68.93
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
IONS: 68.93
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -3251.2, Med: -21.85, Max: 1026.9
Current: 68.93
-3251.2
1026.9
EV-to-Revenue 10.57
EV-to-Revenue ranked higher than
57.07% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
IONS: 10.57
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 3.7, Med: 11.4, Max: 43.4
Current: 10.57
3.7
43.4
Current Ratio 9.40
Current Ratio ranked higher than
71.60% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
IONS: 9.4
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.27, Med: 5.24, Max: 9.89
Current: 9.4
1.27
9.89
Quick Ratio 9.36
Quick Ratio ranked higher than
71.97% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
IONS: 9.36
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.27, Med: 5.06, Max: 9.89
Current: 9.36
1.27
9.89
Days Inventory 1.00
Days Inventory ranked lower than
100.00% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
IONS: 1
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 1, Med: 1861.5, Max: 1861.5
Current: 1
1
1861.5
Days Payable 2.00
Days Payable ranked lower than
100.00% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
IONS: 2
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 2, Med: 5747.75, Max: 5747.75
Current: 2
2
5747.75

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -3.70
3-Year Share Buyback Rate ranked higher than
87.75% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
IONS: -3.7
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -31.9, Med: -7.9, Max: -0.8
Current: -3.7
-31.9
-0.8

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 7.98
Price-to-Tangible-Book ranked lower than
73.60% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
IONS: 7.98
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.71, Med: 8.5, Max: 191.18
Current: 7.98
1.71
191.18
Price-to-Projected-FCF 3.27
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
50.26% of 193 companies
in the Biotechnology industry.
Industry Max: 117, Med: 3.12, Min: 0.09
IONS: 3.27
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 2.67, Med: 15.82, Max: 564.67
Current: 3.27
2.67
564.67
Price-to-Median-PS-Value 0.97
Price-to-Median-PS-Value ranked higher than
57.67% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
IONS: 0.97
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.2, Med: 0.95, Max: 5.12
Current: 0.97
0.2
5.12
Price-to-Graham-Number 3.07
Price-to-Graham-Number ranked lower than
100.00% of 200 companies
in the Biotechnology industry.
Industry Max: 68.46, Med: 2.27, Min: 0.02
IONS: 3.07
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 3.06, Med: 15.05, Max: 32.88
Current: 3.07
3.06
32.88
Earnings Yield (Joel Greenblatt) % 1.27
Earnings Yield (Greenblatt) ranked higher than
73.54% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
IONS: 1.27
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -12.8, Med: -1.3, Max: 2
Current: 1.27
-12.8
2

More Statistics

Revenue (TTM) (Mil) $ 752.47
EPS (TTM) $ 2.51
Beta 1.82
Volatility % 37.44
52-Week Range $ 40.91 - 86.58
Shares Outstanding (Mil) 140.32

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 7
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y